TILT-123
- Generic Name
- TILT-123
- Drug Type
- Biotech
TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma
Phase 1
Recruiting
- Conditions
- Metastatic Melanoma
- Interventions
- First Posted Date
- 2025-05-08
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- TILT Biotherapeutics Ltd.
- Target Recruit Count
- 9
- Registration Number
- NCT06961786
- Locations
- 🇩🇰
National Center for Cancer Immune Therapy Herlev Hospital, Copenhagen University, Copenhagen, Denmark
Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer
- First Posted Date
- 2023-11-09
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- TILT Biotherapeutics Ltd.
- Target Recruit Count
- 22
- Registration Number
- NCT06125197
- Locations
- 🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸UCLA Jonsson Comprehensive Cancer Center, Santa Monica, California, United States
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a and 2) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.
Phase 1
Recruiting
- Conditions
- Platinum-refractory Ovarian CarcinomaPlatinum-resistant Ovarian CancerPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaPlatinum-Refractory Fallopian Tube CarcinomaPlatinum-Refractory Primary Peritoneal CarcinomaPlatinum-Sensitive Ovarian Cancer in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or CisplatinPlatinum-Sensitive Fallopian Tube Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or CisplatinPlatinum-Sensitive Primary Peritoneal Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin
- Interventions
- First Posted Date
- 2022-03-09
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- TILT Biotherapeutics Ltd.
- Target Recruit Count
- 76
- Registration Number
- NCT05271318
- Locations
- 🇺🇸
Gabrail Cancer and Research Center, Canton, Ohio, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Northwell Heatlh/Lenox Hill Hospital, New York City, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath